Literature DB >> 20570669

The prevalence and diagnostic value of perinuclear antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies in patients with inflammatory bowel disease in mainland China.

Feng Zhou1, Bing Xia, Fubing Wang, Umid Kumar Shrestha, Min Chen, Honglin Wang, Xianyan Shi, Zhitao Chen, Jin Li.   

Abstract

BACKGROUND: Perinuclear anti-neutrophil cytoplasmic (pANCA) and anti-Saccharomyces cerevisiae antibodies (ASCA) have been studied extensively in Western countries. We determined the prevalence of pANCA and ASCA in the mainland Chinese population and the ability of pANCA and ASCA to discriminate between ulcerative colitis (UC) and Crohn's disease (CD).
METHODS: Two hundred-six unrelated patients with IBD (UC, n=152; CD, n=54), 60 patients with other gastrointestinal diseases, and 80 healthy controls were included. Sera pANCA and ASCA titers were determined by a standardized indirect immunofluorescence technique.
RESULTS: The sensitivity, specificity, positive and negative predictive values, and positive likelihood ratio of pANCA were calculated for differentiating UC from healthy controls (43.4%, 96.3%, 95.7%, 47.2%, and 11.7, respectively) and ASCA for differentiating CD from healthy controls and (46.3%, 96.3%, 89.3%, 72.6%, and 12.5, respectively). The combination of pANCA and ASCA did not result in greater diagnostic efficiency than either test alone. pANCA was more frequent in UC with extensive or severe phenotype than others. ASCA was associated with severe CD disease activity.
CONCLUSIONS: pANCA and ASCA are useful in confirming the diagnosis of IBD and differentiating between UC and CD in an IBD cohort in central China. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20570669     DOI: 10.1016/j.cca.2010.05.041

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  6 in total

1.  Anti-Saccharomyces cerevisiae antibodies associate with phenotypes and higher risk for surgery in Crohn's disease: a meta-analysis.

Authors:  Zhaoxia Zhang; Chen Li; Xinmei Zhao; Chaolan Lv; Qiong He; Shan Lei; Yandong Guo; Fachao Zhi
Journal:  Dig Dis Sci       Date:  2012-06-06       Impact factor: 3.199

2.  Serologic testing of a panel of five antibodies in inflammatory bowel diseases: Diagnostic value and correlation with disease phenotype.

Authors:  Zhi-Zhi Wang; Ke Shi; Jie Peng
Journal:  Biomed Rep       Date:  2017-02-17

3.  Ulcerative Colitis in Hematological Malignancies: Paraneoplastic Manifestation or Coincidental Bystander?

Authors:  Gregorios Christodoulidis; Konstantinos Perivoliotis; Anastasios Manolakis; Alexandros Diamantis; Apostolos Koffas; Dimitrios Magouliotis; Vasiliki Pappi; Dimitrios Zacharoulis
Journal:  Case Rep Gastrointest Med       Date:  2020-03-23

4.  Role of Serum Proteinase 3 Antineutrophil Cytoplasmic Antibodies in the Diagnosis, Evaluation of Disease Severity, and Clinical Course of Ulcerative Colitis.

Authors:  So Imakiire; Hidetoshi Takedatsu; Keiichi Mitsuyama; Hideto Sakisaka; Kozo Tsuruta; Masaru Morita; Nobuaki Kuno; Koichi Abe; Sadahiro Funakoshi; Hideki Ishibashi; Shinichiro Yoshioka; Takuji Torimura; Fumihito Hirai
Journal:  Gut Liver       Date:  2022-01-15       Impact factor: 4.519

Review 5.  Biomarkers of inflammatory bowel disease.

Authors:  Yi Fengming; Wu Jianbing
Journal:  Dis Markers       Date:  2014-05-19       Impact factor: 3.434

6.  Diagnostic Potential of Zymogen Granule Glycoprotein 2 Antibodies as Serologic Biomarkers in Chinese Patients With Crohn Disease.

Authors:  Shulan Zhang; Ziyan Wu; Jing Luo; Xuefeng Ding; Chaojun Hu; Ping Li; Chuiwen Deng; Fengchun Zhang; Jiaming Qian; Yongzhe Li
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.